New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:26 EDTOMEROmeros shares oversold, secondary endpoint met, says Maxim
Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
09:23 EDTOMEROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perion Network (PERI), up 10.2%... Array Biopharma (ARRY), up 5.6%... Camtek (CAMT), up 4.9%... Frontier Communications (FTR), up 7%. ALSO HIGHER: Lexicon Pharmaceuticals (LXRX), up 32.2% after TELESTAR Phase 3 study met primary endpoint... OraSure Technologies (OSUR), up 7.5% after receiving FDA emergency use authorization for ebola rapid diagnostic test... Omeros (OMER), up 7.1% after receiving marketing authorization for Omidria from EC... Ford (F), up 1.3% after reporting July U.S. sales. DOWN AFTER EARNINGS: Tyson Foods (TSN), down 8.8%. ALSO LOWER: LinnCo (LNCO), down 4.9% after being downgraded to Sector Perform from Outperform at RBC Capital... Linn Energy (LINE), down 5% after being downgraded to Sector Perform from Outperform at RBC Capital.
07:03 EDTOMEROmeros announces EC granted marketing authorization for Omidria
Subscribe for More Information
July 23, 2015
07:28 EDTOMEROmeros' aHUS candidate granted Fast Track designation by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use